TIDMTRX

RNS Number : 4237Q

Tissue Regenix Group PLC

26 February 2021

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Directorate Change

Leeds, 26 February 2021 - Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that the Board has appointed Jonathan Glenn, current Interim Non-Executive Chairman, to the position of Non-Executive Chairman with immediate effect.

Jonathan joined the Group in January 2016, and was appointed Interim Non-Executive Chairman in March 2020.

Daniel Lee, Chief Executive Officer, of Tissue Regenix Group plc said: "We are delighted to have Jonathan appointed as Non-Executive Chairman to the Group. Jonathan's leadership has been invaluable over the last year, as Interim Chairman, and we look forward to his continued contribution towards the Company's future growth."

For more Information:

 
 Tissue Regenix Group plc                            www.tissueregenix.com 
  David Cocke, Chief Financial Officer                     Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated              Tel: +44(0)20 7710 
  Adviser and Broker)                                                 7600 
  Ben Maddison / Alex Price 
 
 Walbrook PR Ltd                                       Tel: +44 (0)20 7933 
  Alice Woodings / Lianne Cawthorne / Paul                            8780 
  McManus                                     TissueRegenix@walbrookpr.com 
 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAPPUQGPUPGGRA

(END) Dow Jones Newswires

February 26, 2021 02:00 ET (07:00 GMT)